Dubey G K, Joglekar V K, Hardas U D, Chaubey B S
Lepr India. 1981 Apr;53(2):197-203.
This paper presents a review of 123 cases of leprosy of different clinical types as regards to their status of cellular immunity. These 123 cases included 41 fresh cases, 18 cases of reaction and 64 cases of leprosy taking antileprosy treatment. Out of 41 untreated cases only 11 turned up for follow up and their lymphoblastic transformation was repeated 4 to 6 months after initiating the treatment. It was observed that cell mediated immunity as expressed in terms of percentage of blast cells is definitely depressed in leprosy, most in LL and least in TT. There is a definite increase in the percentage of blast cells after taking antileprosy treatment. The rise in percentage of blast cells and hence cellular immunity is relatively more in patients treated with Lamprene as compared to those treated with DDS. Reactions also have impact over immunity in leprosy. Thus, most of the patients with ENL show higher values for blast percentage as compared to those with lepra reaction. It appears that serial lymphocyte cultures if done in all cases of leprosy undergoing treatment will help in assessment of individual progress.
本文就123例不同临床类型麻风病患者的细胞免疫状态进行了综述。这123例患者包括41例新发病例、18例反应期病例和64例正在接受抗麻风治疗的病例。41例未治疗病例中，只有11例前来接受随访，其淋巴细胞转化在开始治疗后4至6个月重复进行。观察发现，以母细胞百分比表示的细胞介导免疫在麻风病中确实受到抑制，在LL型中最为明显，在TT型中最不明显。接受抗麻风治疗后，母细胞百分比有明显增加。与接受DDS治疗的患者相比，接受氯苯吩嗪治疗的患者母细胞百分比及细胞免疫的升高相对更多。反应期对麻风病的免疫也有影响。因此，与麻风反应患者相比，大多数ENL患者的母细胞百分比更高。看来，对所有接受治疗的麻风病患者进行系列淋巴细胞培养将有助于评估个体病情进展。
